Literature DB >> 20711832

[The minimally invasive anterolateral approach to L2-L5].

Christoph Mehren1, H Michael Mayer, Christoph Siepe, Frank Grochulla, Andreas Korge.   

Abstract

OBJECTIVE: Minimally invasive anterolateral retroperitoneal approach to the lumbar spinal levels L2-L5. INDICATIONS: Anterior interbody fusion for the treatment of degenerative disk disease (DDD), degenerative instability, isthmic and degenerative spondylolisthesis, tumors, degenerative scoliosis, fractures, spondylodiscitis, failed back syndrome (pseudarthrosis, post-diskectomy). CONTRAINDICATIONS: No absolute contraindications. Relative contraindications are previous surgeries via a sinistral retroperitoneal approach or a far lateral anatomy of the left iliac common vein covering the lateral annulus of the disk space L4/5. SURGICAL TECHNIQUE: A small skin incision over the left abdominal wall is followed by a blunt muscle-splitting approach to the retroperitoneal space and the anterolateral circumference of the lumbar spine. A diskectomy, corporectomy and/or grafting (iliac crest or cage) may be performed for a solid ventral fusion. POSTOPERATIVE MANAGEMENT: Early mobilization from the 1st postoperative day in all cases of combined ALIF (anterior lumbar interbody fusion)/ posterior instrumentation procedures. Thromboembolic prophylaxis with fractionated heparin. Light meals up until recovery of the first bowel movements. A brace is recommended depending on the type of the intervention for a duration of up to 12 weeks. No limitations for standing, walking or sitting in the immediate postoperative period.
RESULTS: Minimally invasive anterior interbody fusion procedures with iliac crest bone graft were performed in 120 patients (average age 56.3 years, range 26-84 years) in combination with a dorsal instrumentation. 16 patients were treated with a double-level procedure. Duration of surgery ranged between 50 and 192 min (mean 102.2 min). The intraoperative blood loss was 67.3 cm(3). At the 6-month follow-up, the fusion rate was 95.6%. No vessel, bowel, kidney or spleen injuries were observed.

Entities:  

Mesh:

Year:  2010        PMID: 20711832     DOI: 10.1007/s00064-010-8054-5

Source DB:  PubMed          Journal:  Oper Orthop Traumatol        ISSN: 0934-6694            Impact factor:   1.154


  6 in total

1.  The Oblique Anterolateral Approach to the Lumbar Spine Provides Access to the Lumbar Spine With Few Early Complications.

Authors:  Christoph Mehren; H Michael Mayer; Christoph Zandanell; Christoph J Siepe; Andreas Korge
Journal:  Clin Orthop Relat Res       Date:  2016-05-09       Impact factor: 4.176

2.  Vertebral body stapling as an alternative in the treatment of idiopathic scoliosis.

Authors:  P D Trobisch; A Samdani; P Cahill; R R Betz
Journal:  Oper Orthop Traumatol       Date:  2011-07       Impact factor: 1.154

3.  Biomechanical comparison of anterior lumbar screw-plate fixation versus posterior lumbar pedicle screw fixation.

Authors:  Lie-Hua Liu; Cong-Tao Guo; Qiang Zhou; Xiao-Bing Pu; Lei Song; Hao-Ming Wang; Chen Zhao; Shi-Ming Cheng; Yang-Jun Lan; Ling Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

4.  [Thoracolumbar spinal fractures in the elderly : Classification and treatment].

Authors:  K J Schnake; P Bula; U J Spiegl; M Müller; F Hartmann; B W Ullrich; T R Blattert
Journal:  Unfallchirurg       Date:  2017-12       Impact factor: 1.000

Review 5.  A new "keyhole" approach for multilevel anterior lumbar interbody fusion: the perinavel approach-technical note and literature review.

Authors:  R Bassani; A M Querenghi; R Cecchinato; C Morselli; G Casero; D Gavino; S Brock; C Ferlinghetti
Journal:  Eur Spine J       Date:  2018-06-09       Impact factor: 3.134

6.  Custom-made trabecular titanium implants for the treatment of lumbar degenerative discopathy via ALIF/XLIF techniques: rationale for use and preliminary results.

Authors:  Fulvio Tartara; Daniele Bongetta; Giulia Pilloni; Elena Virginia Colombo; Ermanno Giombelli
Journal:  Eur Spine J       Date:  2019-11-06       Impact factor: 3.134

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.